The BeloGal® technology was developed by Double Bond Pharmaceutical and the patent application is in process (PCT /EP2017/025035). A Freedom to Operate search in the U.S. and EU did not reveal any comparable drug delivery technologies. BeloGal is based on biomimetic encapsulation of the active pharmaceutical ingredient (API) with a polymer- and biology-free excipient that radically increases the therapeutic effect of the API at the target site while protecting the remaining healthy tissues from toxic effects. Preliminary results show a 10-fold dose in lungs and 3-4-fold in liver compared to other organs. The technology is currently in development for lung and liver cancer therapies.